The studies presented that HDAC4 played an important role in hypoxic induced angiogenesis, and that pharmalogical inhibition and shRNA against HDAC4 offered a new strategy in anti-cancer therapy through decreasing HIF-1α expression and inhibiting angiogenesis in tumor (Ellis et al. 2009). Here, HIF1A is linked to neoplasm.